文献速递癫痫神经重症与神经感染

氯胺酮治疗超难治性癫痫持续状态

Ketamine to treat super-refractory status epilepticus.
PubMed 文献 · Neurology · 2020-09-01

结果显示81%患者发作负担在24小时内下降至少50%,63%完全停止;氯胺酮与平均动脉压稳定及血管升压药需求减少相关,未增加颅内压。

要点

  • 氯胺酮可使多数SRSE患者发作负担下降,部分完全停止。
  • 高剂量氯胺酮与血管升压药需求减少相关,不增加颅内压。
  • 证据等级为Class IV,支持氯胺酮用于SRSE的辅助治疗。

核心结论

  • 氯胺酮治疗与SRSE患者发作负担下降相关。
  • 高剂量氯胺酮与血管升压药需求减少相关,且不增加颅内压。

研究设计与样本

  • 回顾性连续病例系列,纳入2009至2018年68例接受氯胺酮治疗并监测头皮脑电的SRSE患者。
  • 比较氯胺酮启动后发作停止与未停止的患者。

主要发现

  • 平均年龄53±18岁,46%为女性。
  • 55例(81%)在启动氯胺酮24小时内发作负担下降至少50%,43例(63%)完全停止。
  • 氯胺酮平均输注剂量2.2±1.8 mg/kg/h,中位持续时间2(1-4)天。
  • 启动氯胺酮时咪达唑仑平均剂量1.0±0.8 mg/kg/h,中位在氯胺酮前0.4(0.1-1.0)天开始。
  • 广义线性混合效应模型显示氯胺酮与平均动脉压稳定(OR 1.39,95%CI 1.38-1.40)及血管升压药需求随时间减少相关;对颅内压、脑血流或脑灌注压无影响。

关键数值与推荐

  • 研究提供Class IV证据表明氯胺酮减少SRSE患者发作。

临床怎么用

  • 对SRSE患者可考虑氯胺酮输注以降低发作负担。
  • 高剂量氯胺酮输注时需关注血管升压药需求变化,但无需担心颅内压升高。

局限性

  • 回顾性研究设计,证据等级为Class IV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test ketamine infusion efficacy in the treatment of super-refractory status epilepticus (SRSE), we studied patients with SRSE who were treated with ketamine retrospectively. We also studied the effect of high doses of ketamine on brain physiology as reflected by invasive multimodality monitoring (MMM). METHODS: We studied a consecutive series of 68 patients with SRSE who were admitted between 2009 and 2018, treated with ketamine, and monitored with scalp EEG. Eleven of these patients underwent MMM at the time of ketamine administration. We compared patients who had seizure cessation after ketamine initiation to those who did not. RESULTS: Mean age was 53 ± 18 years and 46% of patients were female. Seizure burden decreased by at least 50% within 24 hours of starting ketamine in 55 (81%) patients, with complete cessation in 43 (63%). Average dose of ketamine infusion was 2.2 ± 1.8 mg/kg/h, with median duration of 2 (1-4) days. Average dose of midazolam was 1.0 ± 0.8 mg/kg/h at the time of ketamine initiation and was started at a median of 0.4 (0.1-1.0) days before ketamine. Using a generalized linear mixed effect model, ketamine was associated with stable mean arterial pressure (odds ratio 1.39, 95% confidence interval 1.38-1.40) and with decreased vasopressor requirements over time. We found no effect on intracranial pressure, cerebral blood flow, or cerebral perfusion pressure. CONCLUSION: Ketamine treatment was associated with a decrease in seizure burden in patients with SRSE. Our data support the notion that high-dose ketamine infusions are associated with decreased vasopressor requirements without increased intracranial pressure. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ketamine decreases seizures in patients with SRSE.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Alkhachroum A, Der-Nigoghossian CA, Mathews E, et al. Ketamine to treat super-refractory status epilepticus. Neurology. 2020. PMID: 32873691. doi:10.1212/WNL.0000000000010611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。